Objective: To compare brain metabolite levels in patients with primary progressive (PP) and relapsing remitting (RR) MS and controls. Hypotheses: (1) creatine (Cr), a putative marker of gliosis, is elevated and N-acetylaspartate (NAA), a putative marker of axonal density and functional integrity, is reduced in PPMS lesions and normal appearing white matter (NAWM) compared to control white matter; (2) The pattern of metabolite change in PPMS is different than in RRMS. Methods: MRI and proton magnetic resonance spectroscopic imaging ( 1 H MRSI) were collected from 15 PPMS patients, 13 RRMS patients, and 20 controls. Results: Cr was increased in PPMS NAWM compared to controls (P=0.035), and compared to RRMS NAWM (P=0.038). Cr was increased in focal MRI lesions from PPMS compared to lesions from RRMS (P=0.044) and compared to control white matter (P=0.041). NAA was similarly reduced in PPMS and RRMS NAWM compared to control. NAA was similarly reduced in PPMS and RRMS lesions, compared to control white matter. Conclusions: Creatine is higher in PPMS than RRMS NAWM and focal lesions. This observation is consistent with the notion that progressive disability in PPMS re¯ects increased gliosis and axonal loss whereas disability in RRMS re¯ects the cumulative effects of acute in¯ammatory lesions and axonal loss. Multiple Sclerosis (2000) 6, 148±155
Introduction
Multiple Sclerosis (MS) is an in¯ammatory demyelinating disease of the central nervous system with distinct clinical subtypes. Approximately 85% of patients initially experience acute onset of symptoms that generally remit spontaneously; this disease subtype is termed relapsing-remitting MS (RRMS). Approximately 50% of RRMS patients eventually experience gradual progression of disability that may or may not be accompanied by acute relapses; this disease subtype is termed secondary progressive MS (SPMS). Approximately 15% of MS patients experience a clinical pattern that is progressive from onset; a subtype termed primary progressive MS 1 (PPMS). The pathological hallmark of all subtypes of MS are focal lesions that are distinguished by their content of activated macrophages and T cells, edema, demyelination, and axonal transection. 2 Each of these histopathologies 3 appears hyperintense on T2-weighted MRI. The white matter, which appears normal on gross pathology, shows mostly astroglial hypertrophy and to a much lesser extent in¯ammatory in®ltrate, demyelination or axonal loss. 4 Multiple lines of evidence suggest that the biology of PPMS differs signi®cantly from that of RRMS and SPMS. Cross-sectional and longitudinal MRI studies indicate that compared to RRMS and SPMS, PPMS patients are more likely to experience: (1) fewer focal intracranial and spinal gadolinium-enhancing and T2weighted MRI lesions; 5 ± 8 (2) more diffuse abnormalities in the white matter of the spinal cord; 9 and (3) more progressive atrophy of the spinal cord as measured by cross sectional diameter at C2 ± 3. 10 Immunological markers of disease activity indicate serum levels of soluble E-selectin are increased in patients with PPMS 11 and cerebrospinal¯uid (CSF) levels of sE-selectin are signi®cantly raised in PPMS compared to RRMS during relapse and remission. 12 PPMS may be genetically distinct from RR and SPMS. 13 ± 15 The extent of in¯ammatory perivascular in®ltrates in lesions is less severe in PPMS than RRMS and SPMS. 16 The possibility that diffuse imaging abnormalities in white matter of PPMS largely re¯ect increased gliosis rather than or in addition to axonal loss has never been explicitly considered. Further, there has never been a rigorous study comparing the histopathology of normal appearing white matter in PPMS, and RRMS.
Although magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopic imaging (MRSI) may improve the histopathological speci®city of T2weighted MR imaging changes observed in MS, 5, 6 there have been few MRS and MRSI studies comparing lesions and normal appearing white matter (NAWM) in PPMS, and RRMS. Most MRS and MRSI studies of patients with MS have measured the following metabolites: N-acetyl aspartate (NAA), which has been suggested to be a marker for neuron viability and axonal density in the brain, 17 Creatine (Cr) which represents a combination of creatine and phosphocreatine, a putative marker of gliosis, 18, 19 and Choline (Cho) thought to be a marker associated with membrane phospholipids. 20 1 H MRS studies of RRMS show reduced NAA/Cr in T2-intense lesions 21 and normal appearing white matter. 22 ± 24 Presumably, these metabolic changes in normal appearing white matter re¯ect microscopic disease 4 and decreased NAA/Cr in lesions and normal appearing white matter of RRMS probably re¯ects decreased NAA and increased Cr. 21, 25, 26 NAA is shown to be similarly reduced in MRI lesions of PPMS and RRMS 27 and NAA is also decreased in normal appearing white matter in PPMS 28, 29 compared to white matter in controls. Nonetheless, a rigorous comparison of NAA and Cr in both lesions and normal appearing white matter in PPMS, RRMS and white matter in controls has never been reported. Previous studies have reported that Cr is increased in RRMS normal appearing white matter compared to white matter of healthy controls. The increased Cr has been attributed to microscopic disease, most likely gliosis. Since PPMS is considered to have much less in¯ammatory disease than RRMS, comparison of Cr levels between RRMS and PPMS could be instructive. If NAA is similarly reduced in PPMS and RRMS normal appearing white matter, an increase in Cr in PPMS normal appearing white matter and focal lesions relative to RRMS would be consistent with the notion that sustained progression of disability in PPMS re¯ects gliosis in addition to in¯ammation and axonal loss.
The goal of this study was to compare levels of Cr and NAA in lesions and normal appearing white matter in PPMS, RRMS and white matter in controls.
The speci®c a priori hypotheses tested were, that compared to control white matter: (1) Cr is increased in PPMS normal appearing white matter and lesions re¯ecting a possible increase in diffuse gliosis and (2) NAA is decreased in PPMS normal appearing white matter and lesions. A secondary objective was to determine whether the pattern of metabolite change was different in RRMS and PPMS and re¯ected known differences in the histopathology of RRMS and PPMS.
Materials and methods

Subjects
This study was approved by the Committee on Human Research at the University of California, San Francisco, and all subjects provided written informed consent prior to MRI and MRS examination. Patients with clinically de®nite MS 30 who met consensus criteria 1, 31, 32 for different clinical disease patterns were enrolled. Fifteen patients with PPMS (ten males and ®ve females; mean age, 47.5 years; mean EDSS score, 4.40; mean disease duration, 9.07 years), 13 patients with RRMS (seven males and six females; mean age, 39.5 years; mean EDSS score, 2.50; mean disease duration 7.79 years), and 20 healthy controls (13 males and seven females; age range 24 ± 59 years; mean age, 41.3 years) were investigated by MRI and long-TE PRESS 1 H MRSI. The lesions of 12 PPMS (5.17+5.2 lesions per MRSI volume of interest) and ten RRMS (3.10+2.5 lesions per MRSI volume of interest) patients were studied, since only these patients had lesions present in the VOI. The subjects with RRMS have been previously studied by MRI/ 1 HMRSI and the results have been reported. 26 Therefore, no a priori hypotheses were tested concerning the RRMS subjects. However, to allow comparison with PPMS, the data from the RRMS subjects was reanalyzed by the identical methods used to analyze the PPMS. The RRMS data was re-®tted with updated automated software and voxel selections were redone to be consistent with how voxels were selected for the PPMS data.
Magnetic resonance imaging
All MR data were acquired on a 1.5 Tesla Magnetom VISION system (Siemens Inc., Germany) equipped with a standard quadrature head coil. Proton density and T2-weighted MRI images were acquired using a double spin echo sequence (TE 20/80 ms, TR 2500 ms, 3 mm slice thickness) angulated parallel to the anterior commisure-posterior commisure (AC-PC) line. Fiftyone axial slices, without gap, were acquired with a 1926256 matrix over a 1806240 mm ®eld of view (FOV).
Magnetic resonance spectroscopic imaging
Water suppressed 2D 1 H MRSI data sets were acquired using a PRESS spin-echo sequence (TE 135 msec, TR 1800 ms). 1 H MRSI data were acquired from two volumes of interest (VOI); the ®rst in the centrum semiovale centered above the corpus callosum and the second was centered on the lateral ventricles as seen in the sagittal scout images. Each of these brick-shaped VOI's was angulated parallel to the AC-PC line and adjusted for each patient to maximize white matter signal while avoiding lipid in the skull and scalp. The 1 H MRSI FOV was 2106210 mm and was obtained using a circular k-space acquisition scheme 33 that encoded 24 steps along each of the major axes. The total number of phase encoding permutations was 448. Since one signal average was collected at each phase encoding step, the total acquisition time was 13 min. The spectroscopy data was apodized in the spatial frequency domain using a Gaussian ®lter that produced an effective voxel size of 2.4 cm 3 . A nonuniform spectral intensity pro®le across the left-right VOI, due to a non-optimized slice-selective refocusing pulse of the PRESS sequence, was corrected using an empirical correction function.
Voxel selection
A neuroradiologist identi®ed MS lesion and normal appearing white matter regions on T2-weighted MRI. Figure 1A shows the area over which spectroscopic imaging was performed by the rectangles on the midsagittal image. Normal appearing white matter voxels were selected from the centrum semiovale VOI ( Figure 1B ) and lesion voxels were selected from the periventricular VOI ( Figure 1C ). The white circles in the ®gures represent the voxels that were selected. A representative 1 H MRSI spectrum is shown in Figure  1D with the Cho, Cr, and NAA resonances labeled. Spectroscopic imaging data were displayed and voxels were selected using a software program that was developed in house. 34 Corresponding periventricular white matter (PVWM) 1 H MRSI voxels were selected from the controls for a spatially analogous (z position) comparison to MS lesion. The maximum number of normal appearing white matter voxels was selected that did not include MS lesions, gray matter, or CSF (through all ®ve 3 mm MRI slices of each PRESS box, plus one slice above and below the PRESS box). Within the 1 H MRSI imaging plane, selected normal appearing white matter voxels were at least one voxel away from lesions, gray matter, and CSF regions. For the MS lesion, voxels were selected and grouped according to the number of MRI slices in the VOI that each lesion encompassed (one to ®ve slices). Only lesions that were present in at least 60% (three or more MRI slices) of the VOI were averaged. Voxels of the controls were selected from brain regions that were spatially analogous to those of the patients. Voxels between MS patient groups were matched as best as allowed by variances in lesion location and number.
Spectral analysis
1 H MRSI data were zero-®lled to a matrix of 3263261024 points and Fourier transformed. Spectra were ®tted using an automated curve-®tting program that was developed in-house 35 using a Lorentzian-Gaussian lineshape model for the three singlet peaks of Cho, Cr, and NAA. CSF water was used as the standard to normalize the spectroscopy data. 36 Integrated intensities of the three singlet peaks were corrected for coil loading, receiver gain, and normalized to the mean proton density MRI intensity of four CSF regions of interest (ROI). The CSF ROI's were positioned entirely within the lateral ventricles of a proton density image that was acquired during the same session as the spectroscopy data. To avoid contribution from the choroid plexus, the least contaminated CSF ROI's were selected as de®ned by having the greatest intensities on the proton density image. The equation used to normalize the spectroscopy data was:
where Met norm is the normalized metabolite value, Met raw is the raw metabolite value, CSF raw is the intensity of the CSF on the proton density, TV MRSI and TV MRI are the transmitter reference voltages of the MRSI and MRI, respectively, fft MRI is the fft scaling factor of the MRI, and gain MRI and gain MRSI are the receiver gains of the MRI and MRSI, respectively. The fft MRSI does not appear in the equation because it was the same for all 1 H MRSI studies.
Statistical analysis
MRI and 1 H MRSI acquisitions were performed by two different operators, but a single operator performed all data processing. After all the data were acquired and processed, statistical analyses were performed to determine if there was any effect of operator on the data. The results showed some operator dependence for Cho and not for any other metabolites, likely due to systematic differences in the adjustment of water suppression pulses between operators. Since there were no signi®cant between group differences for Cho, this operator dependence has no effect on the data analysis or interpretation.
Values are reported as mean+standard deviation (s.d.). Analysis of variance (ANOVA) was used to assess differences between the control and patient groups. A Benjamini-Hochberg adjustment 37 was used to correct for multiple comparisons as applicable according to the a priori hypotheses of increased Cr and decreased NAA in PPMS. The level of signi®cance was P50.05. Since there were age, EDSS score, disease duration, and number of lesions in the VOI differences between groups, we determined if these variables had any effects on the measures of interest by analysis of covariance (ANCOVA) and regression analysis. An age-dependence was found only for Cr within the control group white matter (Figure 2A) and was corrected using a linear model. All comparisons between the control and patient groups were performed using age-corrected control data. The patient groups did not have an age-dependence for Cr ( Figure  2B ).
Results
Normal appearing white matter
Mean group values of NAA/Cr, and NAA/Cho measures from normal appearing white matter regions are summarized in Table 1 . NAA/Cr of PPMS (1.90+0.11) was signi®cantly decreased compared to RRMS (2.04+0.09, P=0.031) and to controls (2.22+0.19, P=0.027). NAA/Cr in RRMS was also signi®cantly decreased compared to controls (P=0.027), similar to our previous report. 26 NAA/Cr of PPMS, but not RRMS, was signi®cantly related to EDSS score (P=0.025, r 2 =0.67). No signi®cant between group NAA/Cho differences were found. To determine if decreased NAA/Cr in normal appearing white matter was due to change of NAA or Cr, CSF normalized metabolite values were calculated and are shown in Table 1 . Cr was signi®cantly higher in RRMS than controls (P=0.044). This result is consistent with earlier observations. 26 Cr was also increased in PPMS when compared to controls (P=0.035) and RRMS (P=0.038). The differences between patients and controls were not attributable to an interaction between Cr and age and the differences between PPMS and RRMS were not attributable to any interaction between Cr and age, EDSS score, disease duration, or number of lesions in the VOI.
Although NAA in PPMS and RRMS were similar, NAA was lower in normal appearing white matter of PPMS and RRMS than controls (P=0.047 and P=0.047). Thus decreased NAA/Cr in PPMS compared to RRMS re¯ected an increase in Cr in normal appearing white matter of PPMS. In contrast, decreased NAA/Cr in PPMS and RRMS compared to controls re¯ected increased Cr and decreased NAA. Unlike our results for the NAA/Cr ratio, EDSS score was not correlated with NAA and Cr separately.
Focal T2-hyperintense lesions NAA/Cr was signi®cantly reduced in lesions in PPMS and RRMS compared to white matter of controls (P=0.027 and P=0.048). NAA/Cr was similar in PPMS and RRMS and NAA/Cho was similar in PPMS, RRMS, and controls. In contrast to NAA/Cr in normal appearing white matter, NAA/Cr in focal lesions in PPMS and RRMS was not related to EDSS score.
In order to determine whether decreased NAA/Cr in focal lesions was due to change of NAA or Cr, CSF normalized metabolite values were calculated and are summarized in Table 2 . Cr in focal lesions in PPMS was signi®cantly increased when compared to RRMS lesions and control white matter (P=0.044 and P=0.041). In contrast, Cr in RRMS lesions was similar to Cr in control white matter. NAA in PPMS and RRMS lesions was signi®cantly lower than control NAA (P=0.036 and P=0.031). In contrast, NAA in PPMS and RRMS lesions were similar. Thus, decreased NAA/Cr in PPMS compared to controls re¯ected increased Cr and decreased NAA.
Discussion
Our observations indicate: (1) Cr is increased, and NAA decreased in PPMS normal appearing white matter and lesions compared to control white matter; (2) Cr is increased in both normal appearing white matter and lesions of PPMS compared to RRMS; and (3) NAA is similarly decreased in PPMS and RRMS normal appearing white matter and lesions compared to control white matter. These changes were independent of age, degree of disability by EDSS score, differences of disease duration, and number of lesions in VOI. Our results are in accordance with the report by Davie et al, 27 that NAA is similarly reduced in focal lesions of patients with PPMS and RRMS. These results suggest that the extent of axonal dysfunction or axonal density, as measured by NAA, is similar in our sample of PPMS and RRMS.
To the best of our knowledge, this is the ®rst report that Cr is increased in focal lesions and normal appearing white matter of patients with PPMS compared to patients with RRMS. The differences between patients and controls are independent of age and the differences between patients with PPMS and RRMS are independent of differences in age, EDSS score, disease duration, and number of lesions in the VOI.
Converging lines of evidence from natural history, 32,38 histopathology, 2,3 immunology, 13 ± 15 and magnetic resonance imaging 5 ± 8 studies suggest that the biology of PPMS differs signi®cantly from that of RRMS and SPMS. However, fresh brain tissue from these patients is dif®cult to obtain, and as a result, rigorous histopathological studies to quantify and compare the extent of demyelination, axonal loss and gliosis in lesions and normal appearing white matter in PPMS and RRMS are lacking.
There is a notion that 1 H MRSI and magnetization transfer ratio (MTR) may provide surrogate markers of irreversible tissue damage in MS. 1 H MRS and 1 H MRSI provide quantitative measures of brain metabolites that have more histopathological speci®city than conventional T2-weighted imaging. For example, measures of NAA, a putative marker of neuronal functional integrity and density, and the ratio NAA/ Cr correlate more robustly with level of neurologic impairment and disability than measures of T2weighted lesion load. 39 That NAA/Cr is reduced in lesions 21 and normal appearing white matter 22, 23 in RRMS when compared to controls suggests that focal and diffuse axonal loss contribute to disability in these patients. However, NAA/Cr may also re¯ect changes in Cr, a putative marker of gliosis. 18, 19 The possibility that gliosis is a signi®cant contributor to disability has never been explicitly considered in reports of 1 H MRSI in patients with MS. The 1 H MRS Cr signal intensity is much more variable than originally believed. It differs in normals between white and gray matter, it is increased in gray matter in aging, 18 and increases in some disease pathologies. 21, 25, 26 In this study we have observed an increase in white matter 1 H MRS Cr signal intensity with age in healthy controls. That we do not observe an increase in Cr with age in MS patients is likely the result that disease related increases in Cr signal intensity confound an age-related relationship in our small cohort of patients. The variability of the 1 H MRS Cr signal stresses the importance of absolute quantitation to improve the ability to interpret 1 H MRS data. Our observations show that: (1) NAA is similarly reduced in PPMS and RRMS normal appearing white matter; and (2) Cr is signi®cantly increased in PPMS normal appearing white matter and lesions when compared to RRMS. These are consistent with the notion that sustained progression of disability in PPMS re¯ects diffuse gliosis and axonal loss, in contrast to RRMS where sustained progression of disability re¯ects diffuse axonal loss and multifocal in¯ammation.
We have considered the possibility that increased Cr observed in our patients with PPMS may re¯ect factors other than clinical subtype. First, our patient sample was small and may not be representative of the larger population of patients with PPMS and RRMS. We think this is unlikely because the clinical characteristics of our patients are typical of those reported by others. 32, 38 Second, lower Cr in RRMS compared to PPMS might re¯ect dilution resulting from more pronounced microscopic in¯ammation and edema. We think this is unlikely because NAA was similar in patients with PPMS and RRMS. Third, Cr increased with age in the control group. Thus, since the age at onset of disease is on average older for patients with PPMS than RRMS, it is possible that differences in age explain cross-sectional differences in Cr. We think this is unlikely because differences in Cr between patient groups persisted after controlling for differences in age and disease duration. Fourth, the PPMS group had on average a larger fraction of focal lesional white matter within the selected VOIs. Thus, since there is a negative correlation between NAA/Cr and distance from focal lesions, 21 it is possible that higher Cr in PPMS could be due to the greater number of visible focal lesions in that group. We think this is unlikely because we speci®cally selected normal appearing white matter voxels that were most distant from visible focal MS lesions, and also showed by ANCOVA that the metabolite differences were not dependent on the number of lesions in the VOI. The choice to study only large lesions, those present in at least 60% of the VOI, may have biased the results. However, large lesions needed to be used in order to minimize partial voluming effects. The results may be limited by the use of one-sided tests of signi®cance and multiple comparison corrections.
We have also considered technical limitations that might in¯uence the results of our study. First, the coarse spatial resolution of MRSI raises the possibility that data from lesions or normal appearing white matter was`contaminated' by volume averaging from adjacent gray matter, CSF, or nearby focal lesions. Although voxels were carefully selected to include predominantly white matter for the normal appearing white matter data and lesion for the lesion data, contributions from other tissue types or partial-volume effects cannot be avoided due to the coarse spatial resolution of MRSI. In order to reduce spatially dependent sampling bias between groups, voxels were carefully selected to have virtually identical spatial distributions in all three Multiple Sclerosis groups. Also, an automated ®tting program was used to eliminate operator bias and increase the number of voxels observed. Second, since signal intensities were not corrected for relaxation differences, metabolite changes observed may be due to altered relaxation properties. Finally, the equation used to normalize the spectroscopy data assumes identical T1 and T2 of CSF water and similar partial volume effects between subject groups.
In summary, our data con®rm and extend previous reports that NAA in PPMS and RRMS normal appearing white matter and focal lesions is reduced when compared to controls. These observations are consistent with the notion that sustained progression of disability in MS is in part attributable to axonal loss. 40 That creatine is signi®cantly more increased in PPMS than RRMS normal appearing white matter and focal lesions is consistent with the notion that sustained progression of disability in PPMS re¯ects diffuse gliosis and axonal loss. In contrast, sustained progression of disability in RRMS re¯ects diffuse axonal loss and multifocal in¯ammation. Quantitative histopathological examinations of normal appearing white matter and focal lesions in patients with PPMS and RRMS will be necessary to test this hypothesis.
